In this episode, Dennis Walker is joined by Dr. Sam Zand and Derek Du Chesne, co-founders of Better U, to share the story of how they are helping to transform the narrative around seeking out mental health treatments, and to discuss how the stigma around mental health is being eradicated and replaced with a culture of self-love and acceptance.
![MindMed Stock Price Targets [How HIGH can $MMED / $MMEDF Go?]🚀](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-44-600x338.jpeg)
Today we are going to discuss my 5 year price targets for MindMed, MMEDF on the American OTC market, MMED on the Canadian Neo market and MMQ on the European Frankfurt Stock exchange.
Piggy backing off of a decades worth of positive research showing that substances like LSD, Ibogaine, psilocybin and MDMA can treat mental health illnesses better than current methods by an order of magnitude, MindMed is in my opinion by far the most advanced psychedelic medicines company that retail investors can buy on the public markets which is why MindMedicine is one of my top psychedelic stocks in 2021.
In this video, we’re going to look at 4 different 5 year price targets for MindMed, and assign them a level of probability. The four cases will be:
1. The 5 year bear case for MindMed’s stock
2. The Neutral case for MindMed LT
3. The bull case price target for MindMed
4. The Super Bull case
Timestamps:
0:00 – Intro
2:54 – The Bear Case for MindMed
5:37 – The Neutral Case/ MindMed’s Stagnation
7:49 – The Bull Case for MMED/MMEDF Stock
10:18 – The Super Bull Case for MindMed
13:08 – Note of Caution Plus Answer to Meor’s Nasdaq question
Just as a brief note, in this video we are going to be using MMEDF, and all figures will be in American dollars
And because this is all going to be speculation, the entirety of the episode will take place in, The Speculation Zone
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
The good news is that if we can get the nervous system unstuck, we’ll stop feeling so anxious and depressed. Thankfully, there are some fantastic tools for fixing nervous system dysregulation.
Two doses of psilocybin over a period of eight weeks significantly reduced alcohol use and cravings for alcoholics. That’s according to early results of a New York University phase 2 study.
The revered wellness brand wields proven business savvy to innovate, disrupt and equalize through its ketamine clinics.
“Psychedelics and plant-based medicines are powerful tools in the process of healing, particularly for the most marginalized folks living under empire, who are underserved, underrepresented and experience the highest rates of violence. Marginalized communities already have limited access to healing spaces, so I think t’s important for folks invested in justice work to center and prioritize what nontraditional forms of healing look like for these communities.”
MagicMed Industries’ CEO, Dr. Joseph Tucker, talks about their psychedelic library, the company’s plans to go public and what the future of psychedelic research looks like.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
